Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

被引:487
作者
Stephenson, AJ
Scardino, PT
Eastham, JA
Bianco, FJ
Dotan, ZA
DiBlasio, CJ
Reuther, A
Klein, EA
Kattan, MW
机构
[1] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA
[2] Glickman Urol Inst, Cleveland, OH USA
[3] Mem Sloan Kettering Canc Ctr, Dept Urol, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY USA
关键词
D O I
10.1200/JCO.2005.01.867
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A postoperative nomogram for prostate cancer recurrence after radical prostatectomy (RP) has been independently validated as accurate and discriminating. We have updated the nomogram by extending the predictions to 10 years after RP and have enabled the nomogram predictions to be adjusted for the disease-free interval that a patient has maintained after RP. Methods: Cox regression analysis was used to model the clinical information for 1,881 patients who underwent RP for clinically-localized prostate cancer by two high-volume surgeons. The model was externally validated separately on two independent cohorts of 1,782 patients and 1,357 patients, respectively. Disease progression was defined as a rising prostate-specific antigen (PSA) level, clinical progression, radiotherapy more than 12 months postoperatively, or initiation of systemic therapy. Results: The 10-year progression-free probability for the modeling set was 79% (95% CI, 75% to 82%). Significant variables in the multivariable model included PSA (P =.002), primary (P <.0001) and secondary Gleason grade (P =.0006), extracapsular extension (P <.0001), positive surgical margins (P =.028), seminal vesicle invasion (P <.0001), lymph node involvement (P =.030), treatment year (P =.008), and adjuvant radiotherapy (P =.046). The concordance index of the nomogram when applied to the independent validation sets was 0.81 and 0.79. Conclusion: We have developed and validated as a robust predictive model an enhanced postoperative nomogram for prostate cancer recurrence after RP. Unique to predictive models, the nomogram predictions can be adjusted for the disease-free interval that a patient has achieved after RP.
引用
收藏
页码:7005 / 7012
页数:8
相关论文
共 28 条
[21]   Gene expression correlates of clinical prostate cancer behavior [J].
Singh, D ;
Febbo, PG ;
Ross, K ;
Jackson, DG ;
Manola, J ;
Ladd, C ;
Tamayo, P ;
Renshaw, AA ;
D'Amico, AV ;
Richie, JP ;
Lander, ES ;
Loda, M ;
Kantoff, PW ;
Golub, TR ;
Sellers, WR .
CANCER CELL, 2002, 1 (02) :203-209
[22]   Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark [J].
Skuladottir, H ;
Olsen, JH .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3035-3040
[23]   The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? [J].
Stamey, TA ;
Caldwell, M ;
McNeal, JE ;
Nolley, R ;
Hemenez, M ;
Downs, J .
JOURNAL OF UROLOGY, 2004, 172 (04) :1297-1301
[24]   Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy [J].
Stephenson, AJ ;
Smith, A ;
Kattan, MW ;
Satagopan, J ;
Reuter, VE ;
Scardino, PT ;
Gerald, WL .
CANCER, 2005, 104 (02) :290-298
[25]  
Themeau T.M. Grambsch., 2000, MODELING SURVIVAL DA
[26]   The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy [J].
Ward, JF ;
Blute, ML ;
Slezak, J ;
Bergstralh, EJ ;
Zincke, H .
JOURNAL OF UROLOGY, 2003, 170 (05) :1872-1876
[27]   Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer [J].
Wei, JT ;
Dunn, RL ;
Sandler, HM ;
McLaughlin, PW ;
Montie, JE ;
Litwin, MS ;
Nyquist, L ;
Sanda, MG .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :557-566
[28]   Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer [J].
Wheeler, TM ;
Dillioglugil, O ;
Kattan, MW ;
Arakawa, A ;
Soh, S ;
Suyama, K ;
Ohori, M ;
Scardino, PT .
HUMAN PATHOLOGY, 1998, 29 (08) :856-862